Symbols

AORT

Artivion·NYSE

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 6

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Significant Net Income Growth

High Cash/net Profit Ratio

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About AORT

Artivion, Inc.

A leading cardiac and vascular surgery company focused on aortic disease

Industry

Healthcare Equipment and Supplies

Established Date

Listing Date

07/15/1997

Exchange

New York Stock Exchange

Full-time Employees

1,600

Fiscal Year Ends

12-31

Website

www.artivion.com

Security Type

Common stock

Office address

1655 Roberts Boulevard N.W., Kennesaw, GA 30144

Business

Introduction

Incorporated in Florida in 1984 and changing its registered address from Florida to Delaware on January 1, 2022, Artivion, Inc., is a leader in the production, processing and distribution of medical devices and implantable human tissue, focusing on aortic repair. Their medical devices and processing tissues primarily include four product lines: BioGlue Surgical Adhesives (" BioGlue "); On-X Mechanical Heart Valves and Surgical Products; JOTEC Endovascular and Surgical Products; and including CryoValve SG Pulmonary Heart Valves (" CryoValve SGPV ") and CryoPatch SG Pulmonary Heart Patches (" CryoPatch S G ") including heart and vascular human tissue, both of which are processed using its proprietary SynerGraft technology. Other products include CardioGenesis Cardiac Laser Therapy, PerClot and PhotoFixTM.

Earnings Call

Q1/2025

Estimate EPS0.05

Actual EPS0.06

Estimate Revenue94.81M

Actual Revenue99.00M

Artivion's Q1 2025 Earnings Call: Unpacking Key Contradictions in Market Opportunities and Growth Projections

May 12,2025 02:23·
Earnings Decrypt

Company Financials

EPS

AORT has released its 2025 Q3 earnings. EPS was reported at 0.16, versus the expected 0.15, beating expectations. The chart below visualizes how AORT has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

AORT has released its 2025 Q3 earnings report, with revenue of 113.39M, reflecting a YoY change of 18.39%, and net profit of 6.50M, showing a YoY change of 384.18%. The Sankey diagram below clearly presents AORT's revenue sources and cost distribution.